Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 2
1988 1
1989 1
1990 1
1991 1
1992 8
1993 3
1994 6
1995 6
1996 6
1997 8
1998 5
2000 5
2001 6
2002 8
2003 3
2004 1
2005 3
2006 4
2007 1
2008 1
2010 1
2011 1
2014 1
2016 7
2017 4
2018 1
2019 1
2021 1
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. McDermott MSJ, et al. Among authors: presta l. Clin Cancer Res. 2023 Jun 1;29(11):2131-2143. doi: 10.1158/1078-0432.CCR-22-2981. Clin Cancer Res. 2023. PMID: 36884217 Free PMC article. Clinical Trial.
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity.
Weisser NE, Sanches M, Escobar-Cabrera E, O'Toole J, Whalen E, Chan PWY, Wickman G, Abraham L, Choi K, Harbourne B, Samiotakis A, Rojas AH, Volkers G, Wong J, Atkinson CE, Baardsnes J, Worrall LJ, Browman D, Smith EE, Baichoo P, Cheng CW, Guedia J, Kang S, Mukhopadhyay A, Newhook L, Ohrn A, Raghunatha P, Zago-Schmitt M, Schrag JD, Smith J, Zwierzchowski P, Scurll JM, Fung V, Black S, Strynadka NCJ, Gold MR, Presta LG, Ng G, Dixit S. Weisser NE, et al. Among authors: presta lg. Nat Commun. 2023 Mar 13;14(1):1394. doi: 10.1038/s41467-023-37029-3. Nat Commun. 2023. PMID: 36914633 Free PMC article.
An efficient route to human bispecific IgG.
Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. Merchant AM, et al. Among authors: presta lg. Nat Biotechnol. 1998 Jul;16(7):677-81. doi: 10.1038/nbt0798-677. Nat Biotechnol. 1998. PMID: 9661204
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Carter P, et al. Among authors: presta l. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9. doi: 10.1073/pnas.89.10.4285. Proc Natl Acad Sci U S A. 1992. PMID: 1350088 Free PMC article.
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.
Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. Shields RL, et al. Among authors: presta lg. J Biol Chem. 2001 Mar 2;276(9):6591-604. doi: 10.1074/jbc.M009483200. Epub 2000 Nov 28. J Biol Chem. 2001. PMID: 11096108 Free article.
Antibody engineering.
Presta LG. Presta LG. Curr Opin Biotechnol. 1992 Aug;3(4):394-8. doi: 10.1016/0958-1669(92)90168-i. Curr Opin Biotechnol. 1992. PMID: 1368441 Review.
Antibody engineering for therapeutics.
Presta L. Presta L. Curr Opin Struct Biol. 2003 Aug;13(4):519-25. doi: 10.1016/s0959-440x(03)00103-9. Curr Opin Struct Biol. 2003. PMID: 12948783 Review.
Engineering antibodies for therapy.
Presta LG. Presta LG. Curr Pharm Biotechnol. 2002 Sep;3(3):237-56. doi: 10.2174/1389201023378256. Curr Pharm Biotechnol. 2002. PMID: 12164480 Review.
102 results